[{"indications": "Indications\u00a0\n(From 8.1.3 Antimetabolites: British National Formulary)\nTegafur (in combination with uracil) is given by mouth, together with calcium folinate, in the management of metastatic colorectal cancer. Tegafur is a prodrug of fluorouracil; uracil inhibits the degradation of fluorouracil. Tegafur (with uracil) has been shown to be of similar efficacy as a combination of fluorouracil and folinic acid for metastatic colorectal cancer. For NICE guidance on capecitabine and tegafur with uracil for metastatic colorectal cancer, see above.", "name": "TEGAFUR WITH URACIL", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "8 Malignant disease and immunosuppression", "8.1 Cytotoxic drugs", "8.1.3 Antimetabolites", "TEGAFUR WITH URACIL"], "cautions": "Cautions\u00a0see section 8.1; cardiac disease; interactions: Appendix 1 (fluorouracil)", "side-effects": "Side-effects\u00a0see section 8.1 and notes above", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/106027.htm", "doses": ["adult, tegafur 300\u00a0mg/m2 (with uracil 672\u00a0mg/m2) daily in 3 divided doses\r\nfor 28 days; subsequent courses repeated after 7-day interval; for\r\ndose adjustment due to toxicity, consult product literature "], "pregnancy": "Pregnancy\u00a0avoid; manufacturer advises effective contraception\r\nduring and for 3 months after treatment in men or women; see also Pregnancy and Reproductive\r\nFunction"}]